Acetazolamide-based medical therapy

Phase 3Small molecule

Acetazolamide-based medical therapy is one of 11 small molecule programs targeting Intracranial Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial HypertensionActive, not recruiting

Intracranial HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Intracranial Hypertension

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Approved

1 2

Osmitrol

BB. Braun Medical Inc.

Approved

2 3

Ozempic

Novo Nordisk

Phase 3

2 4

Pentothal

AAbbott

Phase 3

1 5

Cisatracurium Besilate

UUniversity Hospital, Clermont-Ferrand

Approved

1 6

Diamox

Teva

Phase 1

4 7

Pentobarbital

UUniversity of California, Los Angeles

Phase 3

1 8

Acetazolamide-based medical therapy

BBeijing Tiantan Hospital

Phase 3

1 9

AZD4017

AstraZeneca

Phase 2

1 10

Nacl

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Intracranial Hypertension

NCT05707442

Clinical

Trials by Indication[1]

Intracranial Hypertension1 trial

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)

Recruiting·—·Phase 3·NCT05707442·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Acetazolamide-based medical therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acetazolamide-based medical therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acetazolamide-based medical therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tiantan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Tiantan Hospital

Acetazolamide-based medical therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Intracranial Hypertension1 trial

References

Drug Info

Quick Facts

Related News